Treatment for Tachycardia

Phase-Based Progress Estimates
Vanderbilt University Medical Center, Nashville, TN
Tachycardia+3 More
18 - 65
All Sexes
What conditions do you have?

Study Summary

Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing. Across-sectional survey found that 25% of these patients complains that meals rich in carbohydrates are among the factors that further exacerbate POTS's symptoms and cause a myriad of gastrointestinal symptoms. The splanchnic circulation is the largest blood volume reservoir of the human body, storing ≈25% of the total blood volume and contributing to sudden, and large, fluctuations in the stroke volume (SV). These orthostatic changes in systemic hemodynamics are particularly magnified after meals, due to increased blood volume sequestration triggered by the release of gastrointestinal peptides with vasodilatory properties. The purpose of this study is to determine if the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling on standing as compare to Healthy controls

Eligible Conditions

  • Tachycardia
  • Postural Orthostatic Tachycardia Syndrome (POTS)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline up to 180 minutes post glucose challenge

Baseline up to 180 minutes post glucose challenge
Change in splanchnic venous capacitance in Postural Orthostatic Tachycardia Syndrome
Measure Glucose-dependent Insulinotropic polypeptide (GIP) hormone level in POTS patients and Controls after 75 grams of glucose ingestion

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline up to 180 minutes post glucose challenge

Trial Background

Prof. Cyndya Shibao, MD
Principal Investigator
Vanderbilt University Medical Center
Closest Location: Vanderbilt University Medical Center · Nashville, TN
Photo of vanderbilt university medical center  1Photo of vanderbilt university medical center  2Photo of vanderbilt university medical center  3
2006First Recorded Clinical Trial
28 TrialsResearching Tachycardia
1019 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between 18 and 50 years of age.
You have a body mass index (BMI) between 18.5 and 29.9 kg/m2.
You are pre-menopausal.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.